Silo Pharma Inc. (NASDAQ: SILO) announced that its board of directors has authorized a share repurchase program to acquire up to $1 million of the company's common stock. The program allows purchases to be made on the open market, through privately negotiated transactions, or by other means, all in compliance with Securities and Exchange Commission rules and applicable legal requirements. As of Nov. 13, 2025, the company reported 13,318,273 shares of common stock outstanding, according to its quarterly report for the period ended Sept. 30, 2025.
The timing and amount of any repurchases will depend on market conditions and corporate and regulatory limitations. The program does not obligate the company to acquire a specific number of shares and may be suspended or discontinued at its discretion. This initiative reflects the board's assessment that the company's stock may be undervalued and represents a strategic use of capital to enhance shareholder value.
Silo Pharma is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company. Its therapeutic focus is on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The company's portfolio includes innovative programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis. Silo's research is conducted in collaboration with leading universities and laboratories.
The repurchase program comes at a time when the biotech sector faces volatility, and such buybacks can signal management's confidence in the company's future prospects. For investors, the program may provide support for the stock price and potentially increase earnings per share by reducing the share count. However, the company retains flexibility and is not bound to complete the repurchases.
For more details on the announcement, visit the full press release at https://ibn.fm/gU3uZ. Additional information about Silo Pharma is available in the company's newsroom at https://ibn.fm/SILO.
